Literature DB >> 6161461

Indications for and results of nephrectomy for metastatic renal cell carcinoma.

A W Middleton.   

Abstract

We find that, when metastases are present, a nephrectomy for renal cell carcinoma is not justified in the vast majority of cases. The only noncontroversial indication is for palliative nephrectomy which is performed to relieve intractable symptoms in the properly chosen patient. However, it is unusual to see a patient with tumor-related symptoms that cannot be conservatively managed. A relative indication for nephrectomy is found in the patient with osseous metastases only, as some studies have demonstrated a prolongation of survival by adjunctive nephrectomy in this setting. Another relative indication is in the patient with limited metastases that are amenable to surgical or radiation ablation coupled with nephrectomy; patients in whom the metastasis appears years after the nephrectomy have the best chance for a successful outcome. When therapy that is effective against metastatic tumor is eventually found, adjunctive nephrectomy as a debulking procedure may become indicated; until then, surgery is not justified. On the basis of data presently available, adjunctive nephrectomy in the hope of inducing spontaneous regression of metastases is never indicated.

Entities:  

Mesh:

Year:  1980        PMID: 6161461

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  2 in total

Review 1.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

2.  The operative challenges of advanced renal cell carcinoma with vena cava involvement: a report of three cases.

Authors:  Muftau Jimoh Bioku; Abdulwaid Niran Saliu; Stephen Odunayo Ikuerowo; Olufunmilade Omisanjo; Julius Olusanmi Esho
Journal:  Case Rep Urol       Date:  2011-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.